DK1355668T3 - Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom - Google Patents

Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom

Info

Publication number
DK1355668T3
DK1355668T3 DK02718052T DK02718052T DK1355668T3 DK 1355668 T3 DK1355668 T3 DK 1355668T3 DK 02718052 T DK02718052 T DK 02718052T DK 02718052 T DK02718052 T DK 02718052T DK 1355668 T3 DK1355668 T3 DK 1355668T3
Authority
DK
Denmark
Prior art keywords
inhibitors
prevention
treatment
heart disease
heart
Prior art date
Application number
DK02718052T
Other languages
English (en)
Inventor
Benjamin Pomerantz
Charles Dinarello
Leonid Reznikov
Alden Harken
Yolande Chvatchko
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Application granted granted Critical
Publication of DK1355668T3 publication Critical patent/DK1355668T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK02718052T 2001-01-29 2002-01-28 Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom DK1355668T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01101959 2001-01-29
PCT/EP2002/000844 WO2002060479A1 (en) 2001-01-29 2002-01-28 Use of il-18 inhibitors for the treatment and/or prevention of heart disease

Publications (1)

Publication Number Publication Date
DK1355668T3 true DK1355668T3 (da) 2008-05-05

Family

ID=8176323

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02718052T DK1355668T3 (da) 2001-01-29 2002-01-28 Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom

Country Status (32)

Country Link
US (1) US20040234523A1 (da)
EP (1) EP1355668B1 (da)
JP (2) JP4860897B2 (da)
KR (1) KR100857376B1 (da)
CN (1) CN1326562C (da)
AR (1) AR032422A1 (da)
AT (1) ATE380558T1 (da)
BG (1) BG66483B1 (da)
BR (1) BR0206819A (da)
CA (1) CA2435466C (da)
CY (1) CY1107203T1 (da)
CZ (1) CZ305653B6 (da)
DE (1) DE60224004T2 (da)
DK (1) DK1355668T3 (da)
EA (2) EA006767B1 (da)
EE (1) EE05534B1 (da)
ES (1) ES2295332T3 (da)
HK (1) HK1062810A1 (da)
HR (1) HRP20030609A2 (da)
HU (1) HU229164B1 (da)
IL (2) IL157024A0 (da)
ME (1) ME00549B (da)
MX (1) MXPA03006776A (da)
NO (1) NO331083B1 (da)
PL (1) PL213568B1 (da)
PT (1) PT1355668E (da)
RS (1) RS51125B (da)
SI (1) SI1355668T1 (da)
SK (1) SK287620B6 (da)
UA (1) UA80676C2 (da)
WO (1) WO2002060479A1 (da)
ZA (1) ZA200305439B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL356836A1 (en) 2000-02-10 2004-07-12 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
AU2002211744B8 (en) 2000-10-11 2008-03-20 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
ATE549353T1 (de) 2003-05-13 2012-03-15 Merck Serono Sa Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
JP4961559B2 (ja) * 2004-03-11 2012-06-27 友昭 星野 インターロイキン１８阻害剤を有効成分とする疾患の予防又は治療剤
CA2609060C (en) 2005-06-03 2014-07-15 Urs Weber Production of recombinant il-18 binding protein
SI1891088T1 (sl) 2005-06-10 2012-02-29 Ares Trading Sa Postopek za äśiĺ äśenje il-18 vezavnega proteina
TW200927060A (en) * 2007-11-05 2009-07-01 Kci Licensing Inc Identification of tissue for debridement
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
KR102321172B1 (ko) * 2013-09-05 2021-11-05 에이비2 바이오 에스에이 염증성 질환에서 il-18 결합 단백질(ｉｌ-18ｂｐ)
SG11201706879UA (en) * 2015-03-05 2017-09-28 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
US11091795B2 (en) 2016-07-11 2021-08-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for diagnosing and treating arrhythmias

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
NZ322197A (en) * 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
WO1998010778A1 (en) * 1996-09-12 1998-03-19 Idun Pharmaceuticals, Inc. INHIBITION OF APOPTOSIS USING INTERLEUKIN-1β-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS
DE69736984T2 (de) * 1996-12-06 2007-09-13 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren des interleukin-1-beta konvertierenden enzyms
KR20000076420A (ko) * 1997-03-18 2000-12-26 스타르크, 카르크 코르티코스테로이드에 대한 반응성을 조절하기 위한 방법 및 조성물
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
DE19743687C1 (de) * 1997-10-06 1998-11-26 Henkel Kgaa Detergensgemische und deren Verwendung
AU4961499A (en) * 1998-06-26 2000-01-17 Eli Lilly And Company 5-HT1f agonists
EP1110969A4 (en) * 1998-09-01 2002-01-09 Hayashibara Biochem Lab INTERLEUKIN 18 BINDING PROTEIN
EP1022027A1 (en) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
AU3876600A (en) * 1999-03-16 2000-10-04 Cytovia, Inc. Substituted 2-aminobenzamide caspase inhibitors and the use thereof
MXPA01010127A (es) * 1999-04-09 2002-08-20 Cytovia Inc Inhibidores de la caspasa y el uso de los mismos.
WO2001003719A2 (en) * 1999-07-09 2001-01-18 Amgen Inc. Combination therapy for conditions leading to bone loss
PL356836A1 (en) * 2000-02-10 2004-07-12 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
PL209371B1 (pl) * 2000-05-05 2011-08-31 Inst Nat Sante Rech Med Zastosowanie inhibitora IL-18, zastosowanie wektora ekspresyjnego zawierającego sekwencję kodującą inhibitor IL-18, zastosowanie genetycznie modyfikowanych komórek wytwarzających inhibitor IL-18 oraz zastosowanie IL-18
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
MXPA03006776A (es) 2003-10-24
HU229164B1 (en) 2013-09-30
PT1355668E (pt) 2008-01-04
CZ305653B6 (cs) 2016-01-27
IL157024A (en) 2014-02-27
BG108128A (bg) 2004-11-30
HUP0303306A3 (en) 2005-12-28
EA200501549A1 (ru) 2006-04-28
KR100857376B1 (ko) 2008-09-05
US20040234523A1 (en) 2004-11-25
EA200300844A1 (ru) 2003-12-25
NO20033228L (no) 2003-09-26
AR032422A1 (es) 2003-11-05
ATE380558T1 (de) 2007-12-15
SI1355668T1 (sl) 2008-06-30
IL157024A0 (en) 2004-02-08
EA006767B1 (ru) 2006-04-28
JP4860897B2 (ja) 2012-01-25
DE60224004D1 (de) 2008-01-24
CZ20032335A3 (en) 2004-07-14
KR20030070143A (ko) 2003-08-27
CN1499982A (zh) 2004-05-26
SK10892003A3 (sk) 2004-02-03
UA80676C2 (en) 2007-10-25
DE60224004T2 (de) 2009-07-23
JP2009102354A (ja) 2009-05-14
NO331083B1 (no) 2011-10-03
NO20033228D0 (no) 2003-07-16
CA2435466C (en) 2012-04-03
WO2002060479A1 (en) 2002-08-08
HRP20030609A2 (en) 2005-06-30
SK287620B6 (sk) 2011-04-05
ZA200305439B (en) 2004-07-15
CA2435466A1 (en) 2002-08-08
JP2004522748A (ja) 2004-07-29
EA010180B1 (ru) 2008-06-30
ME00549B (me) 2011-10-10
PL213568B1 (pl) 2013-03-29
ES2295332T3 (es) 2008-04-16
CY1107203T1 (el) 2012-11-21
CN1326562C (zh) 2007-07-18
BR0206819A (pt) 2004-02-03
YU57803A (sh) 2006-05-25
EE200300328A (et) 2003-10-15
BG66483B1 (bg) 2015-03-31
EE05534B1 (et) 2012-04-16
HUP0303306A2 (hu) 2004-01-28
RS51125B (sr) 2010-10-31
EP1355668A1 (en) 2003-10-29
PL366802A1 (en) 2005-02-07
EP1355668B1 (en) 2007-12-12
HK1062810A1 (en) 2004-11-26

Similar Documents

Publication Publication Date Title
DK1487541T3 (da) Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelse af perifere vaskulære sygdomme
DK1663978T3 (da) Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
NO20044195L (no) Biofosfoninsyrer for behandling og prevensjon av osteoprose
NO20044272L (no) Legemiddel for behandling og/eller forebyggelse av kronisk avstotning
NO20041216L (no) Imidazol-4-karboksamidderivater, fremstilling og anvendelse derav for behandling av overvekt
NO20041872L (no) Esterforbindelser og medisinsk anvendelse derav
DK1427437T3 (da) Oxyntomodulin til forebyggelse eller behandling af overvægt
DK1446122T3 (da) Anvendelse af flibanserin til behandling af uregelmæssigheder ved könsdriften
DK1765388T3 (da) Kombinationsterapi til forebyggelse eller behandling af alzheimer's sygdom, og kit dertil
DE60322451D1 (de) 4-Tetrazolyl-4-Phenylpiperidinderivate zur Schmerzbehandlung
EA200500098A1 (ru) Лекарственное средство и способ лечения патологического синдрома
DK1278540T3 (da) Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelsen af aterosklerose
DK1638589T3 (da) Kombinationsterapi med glatirameracetat og mitoxantron til behandling af multipel sklerose
NO20043370L (no) N-pyrazinylfenylsulfonamider og deres anvendelse ved behandling av kemokinmedierte sykdommer
NO20033854L (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
NO20050569D0 (no) Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette
IS6966A (is) Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
DK1355668T3 (da) Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom
NO20041214L (no) Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer
NO20031806D0 (no) Anvendelse av pericytt apoptosehemmere for behandling og/eller forhindringav diabetisk retinopati
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
ITTO20010848A0 (it) Disposizione e metodo di purificazione o trattamento elettrochimico.
NO20033506L (no) Parasitticidale preparater og metoder for anvendelse
NO20054913D0 (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
DE60222664D1 (de) Hautbehandlungsmittel